88IV - PR Newswire Asia's news


Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance HONG KONG , March 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), ... 2026-03-16T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate MELBOURNE, Australia and INDIANAPOLIS , March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application ... 2026-03-16T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards BioDlink has been named " Emerging CDMO of the Year " for its innovation in complex biologics and ADC development. The award recognizes its proprietary technology platforms, scalable manufacturing, ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy SHANGHAI , March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX- GIP001 , its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation SINGAPORE , March 13, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE SUZHOU, China , March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement — Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — ... 2026-03-13T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Emerald Clinical Trials Honored with 2026 Asia Pacific Biopharma Excellence Award for Outstanding Patient Recruitment & Engagement SINGAPORE , March 12, 2026 /PRNewswire/ -- Emerald Clinical Trials , a leading global clinical research organization (CRO), today announced it has been named a winner of a 2026 Asia Pacific Biopharma ... 2026-03-12T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

PR Newswire Asia's news > Biotechnology